FDA Approves $3.1M Gene Therapy for Rare, Painful Skin DisorderThe FDA has approved Zevaskyn for treating recessive dystrophic epidermolysis bullosa, a rare skin condition, promising improved healing.
New Drug Helps Patients with Myasthenia Gravis Breathe and Speak EasierThe FDA has approved Johnson & Johnson's Imaavy for myasthenia gravis, benefiting over 90% of patients and improving daily tasks.
New FDA-Approved Pill Targets Constant Hunger in Children with PWSFDA approves Soleno's Vykat XR for treating hyperphagia in Prader-Willi Syndrome, aiming to improve patients' quality of life.
Neurocrine's New CAH Drug, Krenicity, Gets FDA Approval—Here’s What You Need to KnowFDA approves Neurocrine Biosciences' Krenicity for congenital adrenal hyperplasia, reducing glucocorticoid dosage in patients.
Must-Reads
1
Man held after hammer attack at Namyangju karaoke bar
LATEST
2
Movies in theaters this week
LATEST
3
[Robert J. Fouser] 2025: A year of testing and triumph
FDA Approves $3.1M Gene Therapy for Rare, Painful Skin Disorder The FDA has approved Zevaskyn for treating recessive dystrophic epidermolysis bullosa, a rare skin condition, promising improved healing.
New Drug Helps Patients with Myasthenia Gravis Breathe and Speak Easier The FDA has approved Johnson & Johnson's Imaavy for myasthenia gravis, benefiting over 90% of patients and improving daily tasks.
New FDA-Approved Pill Targets Constant Hunger in Children with PWS FDA approves Soleno's Vykat XR for treating hyperphagia in Prader-Willi Syndrome, aiming to improve patients' quality of life.
Neurocrine's New CAH Drug, Krenicity, Gets FDA Approval—Here’s What You Need to Know FDA approves Neurocrine Biosciences' Krenicity for congenital adrenal hyperplasia, reducing glucocorticoid dosage in patients.
Hot Topics